Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+B-acute lymphoblastic leukemia patients: A phase ii study

Haematologica

Volumn 100, Issue 4, 2015, Pages e128-e131

  Chevallier, Patrice ^a   Huguet, Francoise ^b   Raffoux, Emmanuel ^c   Etienne, Anne ^d   Leguay, Thibaut ^e   Isnard, Francoise ^f   Robillard, Nelly ^a   Guillaume, Thierry ^a   Delaunay, Jacques ^a   Charbonnier, Aude ^d   Pigneux, Arnaud ^e   Peterlin, Pierre ^a   Bené, Marie C ^a   Wegener, William A ^g   Goldenberg, David M ^g   Dombret, Hervé ^c  

^a HÔTEL DIEU   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d INSTITUT PAOLI CALMETTES   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f HÔPITAL SAINT ANTOINE   (France)

^g IMMUNOMEDICS INC   (United States)

Author keywords

B ALL; CD22; Chemoimmunotherapy; Epratuzumab; Minimal residual disease; Older patients; Refractory; Relapse

Indexed keywords

CD22 ANTIGEN; CYTARABINE; DEXAMETHASONE; EPRATUZUMAB; METHOTREXATE; METHYLPREDNISOLONE ACETATE; PARACETAMOL; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL EVALUATION; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; LETTER; MALE; OVERALL SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY; CLINICAL TRIAL; METABOLISM; MORTALITY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENT DISEASE;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; HUMANS; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; SIALIC ACID BINDING IG-LIKE LECTIN 2; TREATMENT OUTCOME; VINCRISTINE;

EID: 84926291188     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.120220     Document Type: Letter

References (16)

1. Gökbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, haematologica 2015; 100:e130
2. Overall survival for the whole cohort (n=25). prognostic factors, and performance of stem cell transplantation. Blood. 2012;120(10):2032-2041.
3. Gökbuget N. How I treat older patients with ALL. Blood. 2013; 122(8):1366-1375.
4. Raponi S, De Propris MS, Intoppa S, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibodybased immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma. 2011;52(6):1098-1107.
5. Chevallier P, Robillard N, Houille G, et al. Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases. Leukemia. 2009;23(4):806-807.
6. Leonard JP, Coleman M, Ketas JC, et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin’s lymphoma: phase I/II clinical trial results. Clin Cancer Res. 2004;10(16):5327-5334.
7. Micallef IN, Maurer MJ, Wiseman GA, et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood. 2011;118(15):4053-4061.
8. Raetz EA, Cairo MS, Borowitz MJ, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children’s Oncology Group pilot study. J Clin Oncol. 2008;26(22):3756-3762.
9. Advani A, McDonough S, Coutre S, et al. SWOG S0910: A phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukemia. Brit J Haematol. 2014;165:504-509.
10. Chevallier P, Pigneux A, Robillard N, et al. Rituximab for the treatment of adult relapsed/refractory CD20 positive B-ALL patients: a pilot series. Leuk Res. 2012;36(3):311-315.
11. Mohty M, Labopin M, Volin L, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2010;116(22):4439-4443.
12. Ferrari A, Annino L, Crescenzi S, Romani C, Mandelli F. Acute lymphoblastic leukemia in the elderly: results of two different treatment approaches in 49 patients during a 25-year period. Leukemia. 1995; 9(10):1643-1647.
13. O’Brien M, Schiller G, Lister J, et al. High-dose vincristine sulphate liposome injection for advanced, relapsed, refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol. 2013;31(6):676-683.
14. Beldjord K, Chevret S, Asnafi V, et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood. 2014;123(24):3739-3749.
15. Raetz EA, Cairo MS, Borowitz MJ, et al. Reinduction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL) in children, adolescents and young adults: Results from Children's Oncology Group (COG) Study ADVL04P2. Blood. 2011(ASH Annual Meeting Abstracts);118: 573.
16. Chevallier P, Bodet-Milin C, Robillard N, et al. BCR-ABL1 molecular remission after 90Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: proof of principle. Eur J Haematol. 2013;91(6): 552-556.